Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FeTCh-CKD: Oral Iron in Pediatric CKD
NCT03991169Phase 4Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2019
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferrous sulfate in anemia of chronic kidney disease (CKD-A) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Change in muscle strength at 3 months and Change in the percentage of transferrin saturation at 3 months. Started Apr 2019; status: recruiting.
02
Drugs
ferrous sulfate
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03991169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991169.